We studied somatomedin-C/insulinlike growth factor (Sm-C/
Introduction
Cultured human skin fibroblasts have been studied extensively as a model to determine the effects of somatomedins on cell growth and DNA synthesis (1, 2) . Several investigators have analyzed the characteristics of binding of '251I-somatomedin-C/insulinlike growth factor I (Sm-C/IGF-I)' to cultured fibroblasts and compared its binding properties with its cell growth-stimDr. Clemmons is on leave to the National Institutes of Health.
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1. Abbreviations used in this paper: DME, Dulbecco's modified Eagle's medium; DSS, disuccinimidyl suberate; DTT, dithiothreitol; EGF, epidermal growth factor, FCS, fetal calf serum; MEM, Eagle's minimum essential medium; PAGE, polyacrylamide gel electrophoresis; Sm-C/IGF-I, somatomedin-C/insulinlike growth factor-I. ulating properties (3, 4) . To perform binding studies, suspended cell systems have been commonly used (3) (4) (5) . Suspended fibroblasts have been shown to possess two types of somatomedin receptors (6, 7) . The type I receptor has two subunits, Mr = 135,000 (alpha) and 95,000 (beta), and binds Sm-C/IGF-I with a higher affinity than IGF-II and both with a greater affinity than for insulin; whereas the type II receptor has an Mr = 260,000, binds IGF-II preferentially, and does not bind insulin. In order to determine the effects of somatomedins on DNA synthesis, however, adherent monolayer cultures must be used because fibroblasts in suspension do not undergo DNA synthesis and division. Exposure to trypsinization and removal ofthe cells to create suspended cell preparations have been shown to alter the binding of peptide growth factors to cell surface receptors (8) and various conditions such as treatment at 4°C and the use ofchelating agents have been adopted in order to minimize these alterations. It has been reported that human fibroblast monolayers possess specific Sm-C/IGF-I receptors, that bound Sm-C/ IGF-I is fully dissociable, that displacement of bound '251-Sm-C/IGF-I occurs at concentrations of unlabeled Sm-C/IGF-I between 1 and 100 ng/ml (9, 10) , and that insulin when added at a concentration of 10 ,ug/ml displaces >60% of '25I-Sm-C/IGF-I from the monolayers. In contrast other investigators have reported that although there are type I receptors present in fibroblast monolayers, binding to the type I receptor may represent only a small portion of the total '251-Sm-C/IGF-I that is bound (1 1) .
In attempting to perform similar binding studies we were not able to effectively displace labeled Sm-C/IGF-I from fibroblast monolayers using concentrations in the range of 1.0-10 ng/ml, and the addition of insulin resulted in no displacement. Because monolayer cultures are required to demonstrate Sm-C/IGF-I stimulation of replication, we undertook studies using monolayer cultures to define the factors responsible for our inability to displace the labeled peptide effectively and to test the hypothesis that an additional cell surface protein was present that could bind Sm-C/IGF-I but not insulin.
Methods
Cell culture techniques. Human fibroblasts were purchased from the Human Mutant Genetic Cell Repository (Camden, NJ) or obtained from foreskins ofnewborn donors. Fibroblasts that were purchased were dermal in origin and were obtained from donors of varying ages. These include GM-10, 12 wk fetal; GM-4392, 16 wk fetal; GM-4525, 17 wk fetal; GM-1437, newborn; GM-498, 3 yr-, GM-1362, 14 yr, GM-6291, 90 yr-, GM-731, 96 yr. All cultures were plated in plastic petri dishes (Falcon Labware, Oxnard, CA) using Eagle's minimum essential medium (MEM) supplemented with penicillin 100 U/ml, streptomycin 100 Ag/ml, purchased from Grand Island Biological Company (Gibco, Grand Island, NY) and 10% bovine serum (Colorado Serum Co., Denver, CO). Fetal calfserum (FCS), used in some experiments, was purchased from two sources; containing 10% calf serum and were incubated at 370C in a humidified atmosphere containing 5% CO2 and 95% air. The medium was changed every third day and the cells were harvested by trypsinization (trypsin 0.1%, EDTA 0.03%, Gibco) and replated approximately once every 10 d using the split ratio of 1:4. Both stock and test cultures were examined at monthly intervals for Mycoplasma pneumoniae and were found to be uncontaminated. For studies of 251I-Sm-C/IGF-I binding stock cultures were subcultured into 24-well plates (Falcon 3004, 16-mm diam) using a plating density of 10,000 cells/cm2 except where variations in plating density were required to achieve differences in final cell density. Cells were cultured for 3 d in MEM supplemented with 10% FCS then the medium was changed and the incubation continued for an additional 3 d. Cell number was determined in triplicate wells using a Coulter Counter (Coulter Electronics, Inc., Hialeah, FL) on the day that the binding experiment was performed.
Determination of'25I-Sm-C/IGF-I binding to monolayer fibroblast cultures. Quiescent monolayers were washed three times with phosphatebuffered saline (PBS) and then the cultures were exposed to binding medium containing MEM plus Hepes 20 mM and 0.1% bovine serum albumin (BSA) (pH 7.4). '25I-Sm-C/IGF-I (prepared as described below) was added at a concentration of 80,000 cpm/well in a final incubation volume of 0.25 ml. After a 2-h incubation at 80C (there was no further increase in binding during a 3-or 4-h incubation) the medium was aspirated, the cells were washed three times with cold PBS, and then solubilized using 0.3 N NaOH for I h at 220C. Cell lysates were transferred to plastic tubes and '25I-Sm-C/IGF-I that was cell associated was determined in a Beckman gamma spectrometer (Beckman Instruments, Inc., Palo Alto, CA). Nonspecific binding was determined by subtracting the radioactivity bound in the presence ofan excess (1.0 ytg/ml) ofunlabeled Sm-C/IGF-I that had been partially purified by a previously described method ( 12) . Total radioactivity bound was consistently in the range of 5-9% and nonspecific binding was consistently < 15% ofthe total bound or the experiment was discarded. In all experiments in which competition curves were generated, unlabeled Sm-C/IGF-I or insulin was added at increasing concentrations varying between Sm-C/IGF-I 0.1 and 300 ng/ ml or insulin between 1.0 and 10.0 ;ig/ml.
Suspendedfibroblast cultures. Fibroblast cell suspensions to be used for binding studies were prepared as follows: confluent monolayers were treated with 0.1% trypsin in 0.03% EDTA for I min at 24°C and the reaction was stopped by addition of MEM plus 10% FCS. The cells were pelleted then resuspended in 0.25 ml of binding buffer and added to 12 X 75-mm polystyrene tubes (1-1.5 X 106 cells/tube). '25I-Sm-C/IGF-I ( 120,000 cpm) was added to each tube. Tubes were incubated for 2 h at 8°C with agitation every 15 min then washed once with 0.5 ml of PBS and once with 1.0 ml of PBS. After centrifugation the cell pellet was counted.
Preparation ofgrowthfactors. Pure preparations ofSm-C/IGF-I were used in all experiments except to determine nonspecific binding. The purification procedure and criteria for purity have been previously published (13) . Purified Sm-C/IGF-I was iodinated by a modified chloramine-T method (14) to a specific activity of 300 sCi/;g. After iodination the peptide was further purified by affinity chromatography using a Sepharose-linked IgG Sm-C/IGF-I antibody. Impure Sm-C/IGF-I that was used to determined nonspecific binding was purified by acid extraction of acromegalic plasma followed by SP-Sephadex and G-50 Sephadex gel filtration chromatography as previously published (12) . Porcine (PJ-5682) and human insulin were a gift from the Eli Lilly Co. (Indianapolis, IN) . IGF-II was purified by a previously described method and purity was confirmed by amino acid sequencing (15) .
Preparation ofconditioned medium. Quiescent fibroblast or smooth muscle cell monolayers that had been grown to confluency on 10-cm plates were washed three times with PBS and exposed to serum-free MEM for 72 h at 37°C. The conditioned medium was removed, centrifuged at 2,000 g for 15 Gaithersburg, MD).
Results
Between 5% and 9% of the radiolabeled Sm-C/IGF-I bound to the fibroblast monolayers. When increasing concentrations of unlabeled Sm-C/IGF-I (1-20 ng/ml) were added, however, 125I-Sm-C/IGF-I binding increased 40-65% over basal and decreased only when concentrations were increased to between 25 and 300 ng/ml (Fig. 1) . In contrast, when 1251I-Sm-C/IGF-I binding was determined using suspension cultures, low concentrations of Sm-C/IGF-I (0.5-10 ng/ml) displaced significant amounts of the labeled peptide ( Fig. 1 ). To determine whether this phenomenon was limited to one fibroblast strain, monolayer cultures prepared from eight other fibroblast strains were analyzed for the capacity of Sm-C/IGF-I to displace labeled Sm-C/IGF-I. In all the cell lines tested, there was a significant increase in '251-Sm-C/IGF-I binding at low concentrations ( 1-10 ng/ml) and no lines showed >29% displacement at the 50 ng/ml concentration (Table I) Somatomedin -C (ng/ml) Figure 1 . Binding of Sm-C/IGF-I to human fibroblast monolayers and cell suspensions. Human fibroblast monolayers (o) were grown to confluency (85,000 cells/well) as described in methods. After extensive washing with PBS, 0.25 ml of DME containing 25 mM Hepes, 0.1% BSA, pH 7.4 was added. '25I-Sm-C/IGF-I (80,000 cpm/well) was added and the incubation was continued for 2 h at 8°C. The monolayers were then washed three times with PBS, solubilized in 0.3 N NaOH, and the cell-associated radioactivity was determined. Cell suspensions (.) were prepared by exposing monolayer cultures to trypsin 0.1%, EDTA 0.03% for 1 min, and after transfer of 1.5 X 106 cells/ tube in 0.25 ml of buffer, were incubated with 120,000 cpm '25I-Sm-C/IGF-I for 2 h at 8°C. After centrifugation, the cell associated '25I-Sm-C/IGF-I was quantitated. Increasing concentrations of unlabeled Sm-C/IGF-I (0-300 ng/ml) were added simultaneously with '25I-Sm-C/IGF-I to triplicate cultures and each point is the mean value. or when the interval since the last media change prior to performing the binding experiment was varied from 1 to 5 d, Sm-C/IGF-I binding was not altered. If the fibroblast monolayers were exposed to serum-free media for 48 h with two media changes prior to initiation of the experiment, however, the paradoxical increase in Sm-C/IGF-I binding was eliminated but the cultures were still relatively insensitive to competition by unlabeled Sm-C/IGF-I.
To investigate the possibility that in monolayer cultures Sm-C/IGF-I was binding to a site other than the type I receptor, a specific type I receptor monoclonal antibody (alpha-IR3) was added at increasing concentrations to both suspended and (.) were prepared as described in Fig. 1 . After addition of increasing concentrations of insulin (0-10 ,g/ml) the incubations were carried out and cell-associated 1251I-Sm-C/IGF-I was determined as described in Fig. 1 .
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Clemmons et al. (ug/ml) (M) IGF-I in suspension cultures (Fig. 3) . This finding suggests that the '25I-Sm-C/IGF-I is bound to a site other than type I receptor (i.e., a receptor that does not bind insulin such as the type II receptor), and that the type I receptor binding represents only a very low percentage of the total binding observed.
To determine the characteristics of the '25I-Sm-C/IGF-I binding moiety, affinity cross-linking studies were performed. After cross-linking '25I-Sm-C/IGF-I-binding complexes from monolayer cultures were subjected to SDS-PAGE under reducing conditions and autoradiographed. Two major bands (Fig. 4) were observed: a 135,000-mol wt band, characteristic of the alphasubunit ofthe type I receptor, and a more intensely labeled band at 43,000. A less intense band of -260,000 mol wt was also observed. The 260,000-, 135,000-, and 43,000-mol wt bands were either reduced in intensity or obliterated in the presence of 50 ng/ml unlabeled Sm-C/IGF-I. High concentrations of insulin (20 Ag/ml) partially displaced labeled Sm-C/IGF-I from the 135,000-mol wt band and the 260,000-mol wt band, but not from the 43,000-mol wt band (Fig. 4) . Similarly alpha-IR3 inhibited labeling ofthe 135,000-mol wt subunit and the 260,000-mol wt band. In the presence oflow concentrations ofunlabeled Sm-C/IGF-I, however, the intensity of labeling of both the 135,000-and 43,000-mol wt bands was apparently increased (Fig. 5) . To exclude the possibility that the binding protein in the 43,000-mol wt complex was associated with the culture dish or cellular matrix and not the cell surface, the matrix was extracted after cell removal with Triton x-100 and the counts per minute associated with the plastic surface also quantitated. Less than 8% of the total counts bound were detected in either the matrix or the dish.
To confirm that Sm-C/IGF-I binding to a protein in the 43,000-mol wt complex accounted for the lack of insulin displacement, quiescent fibroblast monolayers were suspended by trypsinization and incubated with '25I-Sm-C/IGF-I for 4 h at 8°C in the presence and absence of unlabeled Sm-C/IGF-I or insulin and cross-linked and the proteins were separated by SDS- PAGE. In contrast to the monolayers no binding to the 43,000-mol wt protein was present and the 1251-Sm-C/IGF-I was bound only to the 135,000-mol wt type I receptor (Fig. 6) . The bound '25I-Sm-C/IGF-I could be displaced with either unlabeled Sm-C/IGF-I, insulin, or alpha-IR3. Similar results were obtained if the cells were mechanically removed from the plate and not exposed to trypsin.
To determine whether this binding protein in the 43,000-mol wt complex could be secreted by the fibroblast monolayers into the culture medium, conditioned medium from the fibroblast monolayers was incubated with '25I-Sm-C/IGF-I and reacted with DSS. After separation by PAGE, the '251-Sm-C/IGF-I was cross-linked to three fibroblast media proteins. The molecular weights of the complexes were 43,000, 36,000 and 25,000 (Fig. 7) . The 43,000-and 36,000-mol wt bands were less intensely labeled after addition of unlabeled Sm-C/IGF-I and IGF-II, but not after addition of insulin. In contrast, when conditioned medium was collected for 72 h from suspension cultures and crosslinked to 1251 Sm-C/IGF-I, no 43,000-mol wt binding moiety was detectable (data not shown).
To determine the functional significance of this 43,000-mol wt protein complex, conditioned medium from quiescent fibro- in fibroblast monolayer-conditioned media could alter Sm-C binding to suspended fibroblasts, 120,000 cells/tube were exposed to a 20% (vol/vol) concentration of fibroblast monolayer-conditioned medium (that had been concentrated fivefold) for 14 h at 370C. After addition of increasing concentrations of unlabeled Sm-C (1-10 ng/ml) 1251-Sm-C binding increased -56% above basal at 4 ng/ml then decreased toward control levels.
To confirm that the effect of fibroblast-conditioned medium on 1251-Sm-C binding to smooth muscle cells was associated with attachment of a protein represented in the 43,000-mol wt 1251. Sm-C/IGF-I-protein complex, cross-linking studies were performed using smooth muscle cells that had been exposed to fibroblast-conditioned medium. After exposure to this medium and cross-linking, '251-Sm-C/IGF-I was associated with three proteins in the smooth muscle cell monolayers (Fig. 9) : a 1 35,000-mol wt band that was lessened in intensity in the presence of insulin and obliterated by unlabeled Sm-C/IGF-I, a 43,000-mol wt band that could not be displaced with unlabeled insulin, and a 260,000-mol wt band. In contrast, control cultures that had been exposed to smooth muscle cell-conditioned media showed intense '25I-Sm-C/IGF-I labeling in the 135,000-mol wt band, as well as less intense labeling at 260,000. Both bands were displaced with increasing unlabeled Sm-C/IGF-I or insulin. Ofinterest was the observation that cross-linking ofradiolabeled Sm-C/IGF-I to smooth muscle cell-conditioned media showed that a 35,000-mol wt protein that bound radiolabeled Sm-C was present. Preliminary physicochemical properties of the factor in the 43,000-mol wt '251-Sm-C/IGF-I protein complex are: (a) it is retained by dialysis using 3,500-mol wt exclusion membrane, destroyed by proteases, (b) it is heat stable at 560C for 2 h but partially inactivated by heating to 800C for 1 h, and (c) it is stable at pH 2.5 and 10.6 (Table II) .
Discussion
These findings demonstrate that cultured human fibroblast monolayers secrete a 35,000-mol wt protein (43,000 minus 7,600, the molecular weight of '25I-Sm-C/IGF-I) into culture medium. This protein is capable of binding Sm-C/IGF-I and alters Sm-C/IGF-I binding to fibroblast monolayers. Furthermore, our affinity-labeling and competition studies suggest that it is the major binding species detectable after cross-linking to confluent monolayers. The protein has the characteristics of a Sm-C/IGF-I-binding protein because it is secreted by cultured cells into the media, binds Sm-C/IGF-I avidly, and does not bind insulin. The property that appears to distinguish it from other Sm-C/IGF-I-binding proteins secreted by fibroblasts is that The conclusion that the 35,000-mol wt protein accounts for the differences observed in radiolabeled Sm-C/IGF-I binding between fibroblast monolayers and suspensions is supported by several observations. First, it is associated with the cell lysates of fibroblast monolayers but not the same cells in suspension, suggesting that it is responsible for the differences in displacement of 1251I-Sm-C/IGF-I between these conditions. Second, because the 35,000-mol wt protein does not bind insulin its presence on monolayers may account for the inability of insulin2 to displace labeled Sm-C/IGF-I from monolayers (but not from suspension cultures). Similarly, because antibody to the type I receptor (alpha-IR3) does not recognize the 35,000-mol wt protein, this explains the lack of capacity of alpha-IR3 to displace labeled Sm-C/IGF-I from the monolayers. Third, the suspended fibroblasts do not appear to secrete this protein. Taken Armstrong et al. (23) used placental membranes and noted a band between 40,000 and 45,000 that cross-linked with labeled basic somatomedin. Although in the former study amniotic fluid was thought to be the source of the protein, it is notable that it was not completely removed by washing. Because fibroblasts are present in these tissues it is possible that these authors were cross-linking to a protein related to the one described herein. Finally, multiple studies report somatomedin-binding proteins of similar size in amniotic fluid, serum, and culture media (11, 18, 23) .
Other investigators have prepared human fibroblast membranes from suspension cultures for cross-linking studies and have not reported this protein (7). Because they detached the cells from the monolayer it is possible that the 35,000 protein was removed, or alternately, as shown by Grizzard et al. (22) , it might not have been detected because 5% polyacrylamide gels were used. Our data support the hypothesis that removal of the cells from the plate results in a lower cellular affinity for the 35,000-mol wt protein because exposure of suspended cells to concentrated conditioned media prior to binding studies results in reinstitution of the paradoxical increase in '25I-Sm-C/IGF-I binding. Inasmuch as the suspended cells do not secrete the 35,000-mol wt binding protein its continued synthesis and secretion during the binding experiment may be required for it to be detected. In contrast, when affinity cross-linking studies have been performed by other investigators directly on fibroblast monolayers not only is the type I receptor present but a lower molecular weight IGF-I complex (43,000) is also present (5) . Taken together, these findings suggest that this binding moiety may be important in modifying the binding, and possibly the biologic action of Sm-C/IGF-I in many types of proliferating cells.
These findings are difficult to reconcile with published reports of Rosenfeld and Dollar (9) . They have reported that unlabeled Sm-C/IGF-I displaces significant quantities of labeled peptide from newborn foreskin fibroblast monolayers when added in concentrations of 1-10 ng/ml. In their hands addition of insulin at 8.0 Ag/ml results in a 60% displacement of bound '251-Sm-C/ IGF-I from monolayer cultures, and their results are consistent with the existence of only one class of receptors. Differences between our studies and theirs cannot be attributable to tissue source, donor age, feeding schedule, or preincubation periods, as each were similar or identical. Because these authors did not detail the plating densities utilized nor the purity ofthe peptides employed, it remains possible that those differences account for the discrepancies noted for Sm-C/IGF-I displacement. The discrepancies in the findings of insulin displacement remain unresolved.
These findings indicate that fibroblasts secrete a protein that functions not only to alter Sm-C/IGF-I binding to human fibroblast receptors but also has the potential for altering cellular response to this peptide. Our laboratory has previously described the secretion of a somatomedinlike factor by fibroblasts that augments the cellular response to exogenously added Sm-C/IGF-1 (24) . Therefore, it is possible that the 35,000-mol wt protein represents a closely related factor. Fibroblast DNA synthesis can be stimulated by very low concentrations of Sm-C/IGF-I (e.g., 1-10 ng/ml). This finding indicates that the 35,000-mol wt protein may not be blocking the response to Sm-C/IGF-I in that the relatively high concentrations required for competition in these studies (e.g., 25-300 ng/ml) are not required for replication.
It is possible that this factor actually enhances the cellular responsiveness to exogenously added Sm-C/IGF-I. Secretion of this factor could represent an important signal molecule in cellcell interaction between fibroblasts or between fibroblasts and smooth muscle cells. In this regard there is evidence that after injury to vessel walls fibroblasts may suppress smooth muscle cell division and proliferate in areas where smooth muscle cells previously have dominated (25) . Further studies will be required to analyze the effect of this peptide on smooth muscle cell division.
